Business Description
Diasorin SpA
NAICS : 325413
Compare
Compare
Traded in other countries / regions
DIAS.Austria34D.GermanyDIA.Italy0GZX.UKDSRLF.USA Description
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics--testing done on samples taken from the human body, such as blood and issue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (55% of sales) and molecular diagnostics (35%) and has a total installed base of over 9,000 diagnostic systems. Licensed technologies contribute the remaining 10% of total sales, DiaSorin has a strong presence in Europe, the Middle East, and Africa; the region accounts for the largest portion of company revenue (44%), followed by North America (41%), Asia-Pacific (11%), and Latin America (4%).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | N/A |
N/A
|
N/A
| |||
| Equity-to-Asset | 0.64 | |||||
| Interest Coverage | 18.01 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 5.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.3 | |||||
| 3-Year EBITDA Growth Rate | 24.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | 20.2 | |||||
| 3-Year Book Growth Rate | 24.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 0.17 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.61 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.88 | |||||
| 9-Day RSI | 40.89 | |||||
| 14-Day RSI | 41.28 | |||||
| 6-1 Month Momentum % | -4.04 | |||||
| 12-1 Month Momentum % | -3.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Inventory | 234.64 | |||||
| Days Sales Outstanding | 54.95 | |||||
| Days Payable | 61.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.88 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| 3-Year Dividend Growth Rate | 5.6 | |||||
| Forward Dividend Yield % | 0.88 | |||||
| 5-Year Yield-on-Cost % | 1.3 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.81 | |||||
| Operating Margin % | 29.47 | |||||
| Net Margin % | 20.51 | |||||
| ROE % | 19.58 | |||||
| ROA % | 9.28 | |||||
| ROIC % | 11.93 | |||||
| ROC (Joel Greenblatt) % | 93.06 | |||||
| ROCE % | 13.56 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.16 | |||||
| PE Ratio without NRI | 23.75 | |||||
| Shiller PE Ratio | 37.62 | |||||
| PEG Ratio | 1.34 | |||||
| PS Ratio | 4.75 | |||||
| PB Ratio | 4.01 | |||||
| Price-to-Free-Cash-Flow | 16.22 | |||||
| Price-to-Operating-Cash-Flow | 16.22 | |||||
| EV-to-EBIT | 19.17 | |||||
| EV-to-Forward-EBIT | 23.04 | |||||
| EV-to-EBITDA | 19.17 | |||||
| EV-to-Forward-EBITDA | 18.08 | |||||
| EV-to-Revenue | 5.41 | |||||
| EV-to-Forward-Revenue | 6.55 | |||||
| EV-to-FCF | 18.9 | |||||
| Price-to-Projected-FCF | 1.18 | |||||
| Price-to-DCF (Earnings Based) | 1.09 | |||||
| Price-to-DCF (FCF Based) | 0.72 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1 | |||||
| Earnings Yield (Greenblatt) % | 5.22 | |||||
| Forward Rate of Return (Yacktman) % | 24.47 |
